AN2 Therapeutics, Inc. (ANTX) stock
ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.23−0.24 (-5.37%)
Close on Nov 17, 2026Market cap $159.62MP/E –Yield –
Earnings
AN2 Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 16, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.17
-$0.31 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of AN2 Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 16, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | – | – | -$0.17 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026after the close | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026after the close | – | – | -$0.29 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 17, 2026after the close | – | – | -$0.29 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025after the close | – | – | -$0.31 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025after the close | – | – | -$0.25 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024after the close | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024after the close | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024after the close | – | – | -$0.56 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024after the close | – | – | -$0.57 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | – | – | -$0.65 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | – | – | -$0.81 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023after the close | – | – | -$0.79 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 29, 2023after the close | – | – | -$0.61 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022after the close | – | – | -$0.59 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022after the close | – | – | -$0.53 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | – | – | -$2.98 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
AN2 Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When AN2 Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases AN2 Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- Update
- Update
- Results
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?